Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions
AKRO Stock Forecast
Akero Therapeutics stock forecast is as follows: an average price target of $43.50 (represents a 59.11% upside from AKRO’s last price of $27.34) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AKRO Price Target
The average price target for Akero Therapeutics (AKRO) is $43.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $56.00 to $38.00. This represents a potential 59.11% upside from AKRO's last price of $27.34.
AKRO Analyst Ratings
According to 4 Wall Street analysts, Akero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AKRO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Akero Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 12, 2024 | Edward Nash | Canaccord Genuity | $56.00 | $23.43 | 139.01% | 104.83% |
| Jun 10, 2024 | Andy Chen | Wolfe Research | $40.00 | $22.99 | 73.99% | 46.31% |
| May 15, 2024 | Liisa Bayko | Evercore ISI | $38.00 | $20.30 | 87.19% | 38.99% |
| Oct 11, 2023 | Ed Arce | H.C. Wainwright | $40.00 | $15.04 | 165.96% | 46.31% |
| Sep 13, 2022 | Liisa Bayko | Evercore ISI | $50.00 | $29.05 | 72.12% | 82.88% |
The latest Akero Therapeutics stock forecast, released on Jun 12, 2024 by Edward Nash from Canaccord Genuity, set a price target of $56.00, which represents a 139.01% increase from the stock price at the time of the forecast ($23.43), and a 104.83% increase from AKRO last price ($27.34).
Akero Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $43.50 |
| Last Closing Price | $27.34 | $27.34 | $27.34 |
| Upside/Downside | -100.00% | -100.00% | 59.11% |
In the current month, the average price target of Akero Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akero Therapeutics's last price of $27.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 10, 2024 | Wolfe Research | - | Outperform | Initialise |
| May 15, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 14, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Akero Therapeutics's last stock rating was published by Canaccord Genuity on Jun 12, 2024. The company gave AKRO a "Buy" rating, the same as its previous rate.
Akero Therapeutics Financial Forecast
Akero Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKRO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Akero Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict AKRO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akero Therapeutics's previous annual EBITDA (undefined) of $NaN.
Akero Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-68.24M | $-68.47M | $-66.62M | $-68.47M | $-69.56M | $-58.79M | $-57.38M |
| High Forecast | $-68.24M | $-68.47M | $-66.62M | $-68.47M | $-69.56M | $-54.87M | $-57.38M |
| Low Forecast | $-68.24M | $-68.47M | $-66.62M | $-68.47M | $-69.56M | $-65.97M | $-57.38M |
| Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKRO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akero Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKRO last annual SG&A of $NaN (undefined).
Akero Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.99 | $-0.99 | $-0.96 | $-0.99 | $-1.01 | $-0.85 | $-0.83 |
| High Forecast | $-0.99 | $-0.99 | $-0.96 | $-0.99 | $-1.01 | $-0.79 | $-0.83 |
| Low Forecast | $-0.99 | $-0.99 | $-0.96 | $-0.99 | $-1.01 | $-0.95 | $-0.83 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Akero Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKRO previous annual EPS of $NaN (undefined).
Akero Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
AKRO Forecast FAQ
Is Akero Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Akero Therapeutics (AKRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of AKRO's total ratings.
What is AKRO's price target?
Akero Therapeutics (AKRO) average price target is $43.5 with a range of $38 to $56, implying a 59.11% from its last price of $27.34. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Akero Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AKRO stock, the company can go up by 59.11% (from the last price of $27.34 to the average price target of $43.5), up by 104.83% based on the highest stock price target, and up by 38.99% based on the lowest stock price target.
Can Akero Therapeutics stock reach $40?
AKRO's average twelve months analyst stock price target of $43.5 supports the claim that Akero Therapeutics can reach $40 in the near future.
What are Akero Therapeutics's analysts' financial forecasts?
Akero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-186M (high $-182M, low $-193M), average SG&A $0 (high $0, low $0), and average EPS is $-2.685 (high $-2.629, low $-2.789). AKRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-272M (high $-272M, low $-272M), average SG&A $0 (high $0, low $0), and average EPS is $-3.93 (high $-3.93, low $-3.93).